Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

Regenersis plc (RGS)     

dreamcatcher - 26 Sep 2012 20:57




We help our clients and their customers successfully deploy,
protect, maintain, retire and re-use technology.


The world is witnessing explosive growth in the number of connected devices, and in the power and complexity of mobile computing platforms. This is resulting in an increasing need for sophisticated technology- and user support. Regenersis addresses those needs with a growing portfolio of software-rich services building on a strong heritage of repair operations, customer service and data erasure management.

By combining our capabilities in innovative ways, tailored to individual client requirements, we deliver unique service propositions that reinforce trust in our client’s brands and create value for our business partners and shareholders.


Technology Life Cycle Services

Our international network of repair centres provides product repair, refurbishment, parts management and logistics services for mobile, IT, home entertainment and B2B infrastructure product vendors; and their sales channels, insurers, and end users. Our technically-advanced repair capabilities enjoy a solid reputation with our TMT sector clients, combining service excellence with continuous gains in cost efficiency.

Our industry-leading fault diagnostics and issue resolution technologies include the In-Field Tester for set top boxes, and our SmartChk applications suite for smartphones. These advanced diagnostic platforms improve consumer satisfaction with their devices and materially reduce the incidence and cost of product returns for our clients.

In partnership with leading insurers, our Digital Care operations deliver innovative product insurance and extended warranty programmes for our clients, protecting customers’ investments in mobile technology products.

Our Recommerce division helps manufacturers and retailers to launch products and attract new customers through upgrade and buy-back programmes.

Blancco is the global leader in data erasure management (DEM). Blancco software provides comprehensive data erasure for every type of electronic and magnetic storage media, ranging from portable flash drives and mobile phone memory to solid state drives, networked storage, virtual drives and cloud storage. Blancco DEM is a vital part of any organisation’s security infrastructure, underpinning robust data retention policies and ensuring compliance with international data protection regulations.

Regenersis around the world

Our clients increasingly seek partners who can deliver cost-effective and innovative technology life cycle services on a global basis. Since 2011, Regenersis has expanded its geographical footprint from five countries to 16. With the acquisition of Blancco in April 2014, this increased to 22 countries.



http://www.regenersis.com/about-us



Chart.aspx?Provider=EODIntra&Code=RGS&SiChart.aspx?Provider=EODIntra&Code=RGS&Si




Final Results

http://www.moneyam.com/action/news/showArticle?id=4451090

Financial Highlights

·
Group revenue increased by 13% to £139.9 million (2011: £123.8 million)

·
Headline operating profit(*) increased by 24% to £7.8 million (2011: £6.3 million)

·
Operating cash flow improved to £4.9 million (2011: £2.4 million).

·
Further Improvement in headline operating margin to 5.5% (2011: 5.1%)

·
Net debt reduced to £2.9 million (2011: £3.8 million)

·
Banking facility extended from £15 million to £23.25 million for the period to October 2015, to support further organic investment and incremental M&A activity

·
First dividend payment since 2007 - recommended final dividend of 1.1 pence per ordinary share

ExecLine - 02 May 2015 12:03 - 166 of 183

Obviously, the FD didn't impress the people at the presentation.

Chart.aspx?Provider=EODIntra&Code=RGS&Si

cp1 - 07 May 2015 08:32 - 167 of 183

I don't think this will recover until the FD Dhody gets moved out. He's running this like a family business rather than looking after shareholders. Have you seen the remuneration packages and bonuses dished out last year? The institutions who stumped up 100 million euros at 345p must feel more than done over when they see how he's running things. As ever failure is rewarded once a company has PLC after its name.
The only hope here is if activist Polygon start building a stake and perhaps shake things up. AIM again!

ExecLine - 07 May 2015 12:36 - 168 of 183

Agreed about the FD. He is probably pretty good but someone needs have a word in his ear and maybe send him on a course or two to do with foreign currencies and hedging.

Pity really. It is a bloody good company.

One thing that might possibly happen, is that their software for cleaning disks gets put into operating system software. Now I can't really see that happening unless someone like Samsung takes them over. Or am I talking bollox?

cp1 - 08 May 2015 14:31 - 169 of 183

Taxi for Jog!! Will the city push him? The shareprice suggests so.

Share club meeting Saturday night. I doubt they'll be happy with me having suggested this to them near 350p. Ouch!! I'll keep my head down..

ExecLine - 08 May 2015 22:17 - 170 of 183

As the £GBP strengthens, Regenersis revenue and profits from the Polish Zloty and the Euro get worse.

(I think)

cp1 - 18 May 2015 16:00 - 171 of 183

Even the volume has dropped away here now. In all seriousness how is Dhody still running the finances here??

He's presented to investors (prospective) a few weeks ago (shares down 10% since) great work not.

Why hasn't he sanctioned a share buyback if the shares are such a good investment? It's a question that was asked at the interim presentation.

Why raise so much cash and not grow through acquisitions?

The shares are down a huge 40% from the placing over a year ago and nearly 50% from their peak.

and I thought Hanover were smart cookies!

Someone is accountable or is it a case of snouts in bonus trough???

dreamcatcher - 18 May 2015 16:12 - 172 of 183

You sound just the person for his job. :-))

cp1 - 19 May 2015 10:06 - 173 of 183

I've also noted since they've bought this 'great' company Blancco they've never once mentioned it has won a contract or actually done anything. 1 year and nothing ever mentioned about it. The buying of Blancco coincided with the share price collapse, more than ironic. All a bit strange this one. I think I'll buy a few outside of nominee account pre AGM just for a question and answers laugh. Always fun to see directors stutter and squirm when one asks the questions linking bonuses to share price performance. This one should be a hoot.

dreamcatcher - 14 Jul 2015 16:43 - 174 of 183

Trading Update
RNS
RNS Number : 9273S
Regenersis PLC
14 July 2015






14 July 2015



REGENERSIS PLC

("Regenersis", the "Company" or the "Group")



TRADING UPDATE AND NOTICE OF RESULTS



Regenersis, the global provider of electronic repair, diagnostics and data erasure software, issues this trading update in advance of its results for the year ended 30 June 2015, which will be announced on 22 September 2015.

Notwithstanding Sterling's continued strength through the reporting period, the Group's profitability in the financial year to 30 June 2015 will be in line with market consensus.

Depot Solutions achieved in reported Sterling and in constant currency, growth in revenue and headline operating profit in the year just ended. However, post the year end, Depot Solutions has been notified, following a competitive tender process in which the Group participated fully, that one of its larger clients intends to consolidate its European business with another supplier which is anticipated to adversely impact Depot performance in FY2016. This reflects an ongoing consolidation trend in the sector, of which Depot Solutions has been a beneficiary in recent years.

Blancco (currently reported within Advanced Solutions) achieved year on year sales growth of 27% in its first full year as part of the Group, driving headline operating profit growth in constant currency terms of approximately 45%. The Group will report Blancco separately from the rest of Advanced Solutions at final results and going forwards, reflecting its increasing importance to the Group.

Given the above, the Board believes the outlook for FY2016 is for modest growth in headline operating profit, with strong growth in the Advanced Solutions and Software activities offset by a reduced contribution from Depot activities. During 2016, the Board will focus on actions to maximize shareholder value.

Energeticbacker - 17 Jul 2015 17:40 - 175 of 183

Regenersis PLC featured in our weekly round-up of announcements from AIM, see more at http://www.investorschampion.com/blog/

dreamcatcher - 11 Sep 2015 17:03 - 176 of 183

A company to stay well clear of at the moment .



Naked Trader today - RGS (LON:RGS) kept going down so sold for a loss of £553 . Not sure what's up or not there.

ExecLine - 11 Sep 2015 18:17 - 177 of 183

Final Results Announcement:

22 September 2015

dreamcatcher - 19 Oct 2015 17:45 - 178 of 183

A strong recovery.

Bullshare - 25 Nov 2015 14:14 - 179 of 183

Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.

Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Tuesday 15th December 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Andrew Newland, CEO - Angle (AGL)
• Jog Dhody, CFO - Regenersis (RGS)
• Dr. Satu Vainikka, CEO - Valirx (VAL)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Angle (AGL)
Angle (AGL) 

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

 

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

 

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

·         Early detection of cancer;

·         Personalised cancer treatment;

·         Monitoring of cancer patients during treatment; and

·         Post-treatment monitoring of cancer patients in remission.

Regenersis (RGS)
Regenersis (RGS) 

Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets.

Valirx (VAL)
Valirx (VAL) 

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Sponsored by:
AJ Bell Youinvest
London Stock Exchange

cp1 - 13 Jan 2016 08:50 - 180 of 183

This may well be worth another look with sterling coming off against the euro and falling significantly against the U.S dollar.

Once they sell the after service business then we are looking at a very fast growing pure software business. Certainly could fly if it can recapture 250p area and the sale goes to plan as this morning's rns seems to suggest.

cp1 - 08 Mar 2016 07:56 - 181 of 183

Excellent news. Now the pound isn't killing them, these look to have a very exciting growth business with Blancco. Should start to be re-rated very soon.

cp1 - 08 Mar 2016 09:25 - 182 of 183

Panmure BUY note 320p target.

cp1 - 15 Mar 2016 11:05 - 183 of 183

re-rating afoot....

Been over £4 last year and as I've stated before, the weak pound is very good for this one. Lots of upside to come here folks.
Register now or login to post to this thread.